A TARGETED APPROACH TO ACTIVATE CELLULAR CLEARANCE
Caraway’s therapeutic approach leverages genetic data and unique biological understanding to develop proprietary small molecules that activate cellular clearance and recycling processes – accelerating clearance of accumulated toxic materials and defective cellular components. New insights in genetics highlight the link between lysosomal function and pathologies in multiple organ systems, including the central nervous system (CNS), heart, kidney, and muscle. Caraway is a leader in targeting these mechanisms with potentially disease-modifying compounds for patients suffering the devastating effects of neurodegenerative and rare diseases including Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and lysosomal storage diseases (LSDs).
Caraway’s therapeutic approach leverages genetic data and unique biological understanding to develop proprietary small molecules that activate cellular clearance and recycling processes – accelerating clearance of accumulated toxic materials and defective cellular components. New insights in genetics highlight the link between lysosomal function and pathologies in multiple organ systems, including the central nervous system (CNS), heart, kidney, and muscle. Caraway is a leader in targeting these mechanisms with potentially disease-modifying compounds for patients suffering the devastating effects of neurodegenerative and rare diseases including Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and lysosomal storage diseases (LSDs).
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Founded date: 2018
Investors 2
| Date | Name | Website |
| - | MRL Ventur... | mrlv.com |
| - | SV Health ... | svhealthin... |
Mentions in press and media 5
| Date | Title | Description |
| 26.03.2024 | Dementia Discovery Fund Look Ahead: 2024 is shaping up to be another big year in the fight against dementia | As we approach the second quarter of 2024, the SV Health Investors Partners investing out of the Dementia Discovery Fund (DDF) have summarised the key themes and topics that are likely to be front and centre over the next nine months: 1. St... |
| 08.03.2024 | On International Women's Day SV Venture Partner Ruth McKernan reflects on some achievements of SV biotech portfolio companies | On International Women’s Day it is extremely pleasing to note the vast majority of SV Health Investor’s biotech portfolio companies with women in their C-suite, many being led by female CEOs. It is one of the many reasons I was drawn to wor... |
| 21.11.2023 | Dementia Discovery Fund Announces the Acquisition of Caraway Therapeutics by Merck | This transaction highlights DDF’s attractive strategy of investing in novel therapeutics for dementia, a rapidly escalating public health crisis. |
| 09.06.2021 | Caraway Therapeutics Establishes Collaboration with AbbVie to Develop Novel Small Molecule Therapeutics for Parkinson’s Disease and Other Related Disorders | CAMBRIDGE, MA – June 9, 2021 – Caraway Therapeutics today announced an exclusive, collaboration and option agreement with AbbVie (NYSE: ABBV) to develop and commercialize Caraway’s small molecule therapeutics targeting TMEM175, a potassium ... |
| 09.06.2021 | The Dementia Discovery Fund’s Portfolio Company Caraway Therapeutics Establishes Collaboration with AbbVie to develop small molecule therapeutics targeting Parkinson’s disease and other neurodegenerat... | Boston, MA (US) and London (UK) – June 9, 2021. The Dementia Discovery Fund (DDF) is pleased to announce that Caraway Therapeutics, a portfolio company originally incubated and seeded by DDF and SV Health Investors, has signed an exclusive ... |